CClinicalTrials.gg
CompletedNCT02248350MIGHTYUpdated Feb 15, 2018

An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy

An interventional study of Supervised and Home Based Exercise and Stretching Control Group in Prostate Cancer, Physical Activity and Side-effects, sponsored by Georgetown University. Completed at 1 site in United States. Open to male participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-02-15.

Sponsored by Georgetown University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
Male
01

Study summary

This main purpose of this study is to examine the effects of an exercise intervention to counteract adverse side effects related to Androgen Deprivation Therapy (ADT) in prostate cancer patients. Specifically, a supervised and home-based exercise program will be used to assess its impact on clinical and behavioral variables related to ADT in prostate cancer patients.

Read the detailed description

This study will assess the feasibility of an exercise intervention to counteract adverse side effects related to ADT in prostate cancer (PCa) patients. Specifically, we will use an exercise intervention and assess its impact on bone mass density, Body Mass Index (BMI), hip/waist circumference levels, biomarkers (i.e., glucose, lipids), step count, grip strength, and health-related quality of life (HRQOL) using the Patient Reported Outcomes Measurement Information System (PROMIS®). In this 8-week two-arm randomized clinical trial, 40 PCa patients receiving ADT will be randomly assigned to an exercise (n=20) or a stretching control group (n=20) with a follow-up at 8-weeks.

02

Conditions studied

  • Prostate Cancer
  • Physical Activity
  • Side-effects

Browse trials for

Keywords

  • prostate cancer
  • physical activity
  • exercise
  • intervention
  • side effects
  • androgen deprivation therapy
03

In context

Prostatic Neoplasms

6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.

This study's enrollment of 19 is below the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Georgetown University is the lead sponsor of 286 studies on the registry; 42 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 20 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • (1) Caucasian or African-American/Black men; (2) histologically confirmed non-metastatic PCa; (3) receiving ADT treatment for 9-months or less upon recruitment (and continue to receive treatment during the duration of the study); (4) 40 to 75 years old; (5) sedentary defined as \<60 minutes of recreation or work requiring modest PA/week; (6) ability to perform the level of physical activity assessed by the Physical Activity Readiness Questionnaire (PAR-Q); (6) has access to a smartphone or computer with internet capabilities

Exclusion criteria

Exclusion Criteria:

  • (1) severe cardiac disease; (2) recent myocardial infarction; (3) treated for any other cancer; (4) any physical, psychological illness, and/or medical problems that restricted them from exercise; (5) and not willing or able to follow procedures specified by the study and/or instructions of the researcher.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Exercise Group

    8-weeks of supervised and home based exercise intervention, 3 times a week, 50-minutes a session for a total of 150/minutes a week

    Behavioral: Supervised and Home Based Exercise

  • Active comparator
    Stretching Control group

    Informational booklet containing stretching exercises (20-minutes a day)

    Behavioral: Stretching Control Group

Interventions

  • BehavioralSupervised and Home Based Exercise

    Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.

  • BehavioralStretching Control Group

    Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.

06

What researchers measure

Primary outcomes

  1. Bone Mineral Density

    BMD will be measured by a DXA scan

    Time frame: 8-weeks

Secondary outcomes

  1. Physical Fitness

    . The Bruce treadmill protocol will be used to examine VO2max using a ParvoMedics TrueOne 2400 metabolic cart

    Time frame: 8-weeks

  2. Muscle strength

    Grip strength will be measured in a standardized way (three times in each arm) using a Jamar Dynamometer

    Time frame: 8-weeks

  3. Step Count

    The Fit Bit reliably measures daily steps taken, distance walked, calories burned, and overall activity level.

    Time frame: 8-weeks

  4. Quality of Life (HRQOL)

    The 10-item PROMIS® Global Health Scale will be used to assess key HRQOL domains including pain, fatigue, mental health, physical health, social health, and overall health

    Time frame: 8-weeks

  5. Hip/Waist Circumference

    Anthropometric measures

    Time frame: 8-weeks

  6. Body Mass Index (BMI)

    BMI will be measured according to height and weight

    Time frame: 8-weeks

  7. Glucose/Lipid levels

    A fasting finger stick sample of blood (35 μl) will be assessed for immediate analysis of lipid panel (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, triglycerides) and fasting glucose

    Time frame: 8-weeks

07

Study locations

1 site
  • Office of Minority Health and Health Disparities Research
    Washington, District of Columbia 20003, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02248350
Lead sponsor
Georgetown University
Collaborators
American Cancer Society, Inc.
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Sep 2014
Primary completion
Sep 2017
Completion
Sep 2017
Last update
Feb 15, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion